Figure 2 

This figure illustrates the bidirectional relationship between hallmarks of brain aging and neurodegenerative disease mechanisms, emphasizing the central role of calcium dysregulation. Aging-related processes, such as oxidative stress, mitochondrial dysfunction, and impaired calcium homeostasis, are shown to act upstream of disease-defining pathologies, including Aβ plaques and pTau neurofibrillary tangles in Alzheimer’s disease (AD) or α-synuclein accumulation in Parkinson’s disease (PD). Conversely, these pathological aggregates exacerbate calcium imbalance and other aging hallmarks, creating a vicious cycle that leads to neuronal dysfunction and death. The figure also highlights how aging weakens the brain's resilience to ischemic events, such as stroke, by promoting atherosclerosis and impairing neuronal recovery mechanisms.

A 59-year-old male from British Columbia, Canada, presented with debilitating symptoms of mitral valve prolapse, characterized by progressive fatigue, chest pain, and exercise intolerance. Once an active sprinter, the patient could not climb stairs or perform mild physical activities. Clinical evaluation confirmed the severity of his condition, with a cardiologist warning that his prognosis was poor. In the winter of 2010, the patient began incorporating AIC therapy into his regimen. Within weeks, he reported improved energy levels, and by spring 2011, he progressed from walking on a treadmill to jogging within two months. Over time, his symptoms resolved entirely. As of 2020, the patient remains asymptomatic, with no recurrence of heart-related issues. This case illustrates the potential of AIC therapy to address systemic calcium signaling disruptions and support recovery in patients with mitral valve prolapse.

Conclusion

AIC therapy addresses calcium signaling disruptions that underlie aging-related cellular and systemic dysfunctions. By enhancing mitochondrial function and alleviating ER stress, AIC protects cells from oxidative damage and maintains protein integrity, supporting resilience against age-related decline. Its ability to decalcify tissues and restore calcium homeostasis reduces inflammation and prevents metabolic and cardiovascular complications. These effects contribute to improved systemic communication and cellular function, which is essential for healthy aging and long-term vitality. Clinical evidence, such as the recovery from mitral valve prolapse, demonstrates AIC's potential to reverse degenerative processes, highlighting its relevance for longevity-focused care. As research progresses, AIC therapy offers an innovative pathway to enhance neurological and systemic health, ensuring a more robust aging process.

We offer free 25-minute Zoom consultation sessions for practitioners wanting to know more about AIC Therapy.

Join our community today and get instant access to cutting-edge research on AIC Therapy for your patient’s treatments. Thank you for reading.

Server Bozdogan MD, PhD.

ACRI Research Director

Read about More Benefits from newsletter of AIC Therapy

The Impact of AIC Therapy on Parkinson

Parkinson’s disease progression is closely tied to calcium dysregulation in dopaminergic neurons, where excessive calcium influx disrupts mitochondrial function, promotes oxidative stress, and leads to the toxic aggregation of α-synuclein. AIC therapy addresses these mechanisms by stabilizing calcium signaling between the endoplasmic reticulum and mitochondria, enhancing the sodium/calcium exchanger (NCLX) function, and preventing mitochondrial overload. By maintaining intracellular calcium balance, AIC reduces oxidative damage, prevents calpain overactivation, and limits α-synuclein clumping, which is critical for protecting neurons and preserving energy production. Clinical observations, such as the case of a 75-year-old Parkinson’s patient who experienced reduced tremors and improved quality of life, further demonstrate AIC’s potential in symptom relief and functional recovery. Figures presented in the newsletter provide visual insights into the pathological cycle of calcium overload and its downstream effects, emphasizing AIC’s role in breaking this cycle. Mechanistically, AIC therapy offers not just symptomatic relief but also a targeted approach to correcting the core processes driving neurodegeneration in Parkinson’s disease.

Disclaimer

The information provided in this newsletter is intended for educational and informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment options. Never disregard professional medical advice or delay seeking it because of something you have read in this newsletter. This newsletter does not endorse or recommend any specific treatments, medications, or procedures. Discussing disease conditions and treatment options is based on general information and does not consider individual circumstances. The authors and publishers of this newsletter are not responsible for any adverse effects or consequences resulting from using any suggestions or information contained in the newsletter. Always consult with a healthcare professional before starting any new treatment or changing your existing treatment plan.